Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

অনুরূপ উপাদানগুলি

• Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
  অনুযায়ী: Coates, LC, অন্যান্য
  প্রকাশিত: (2024)
• Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
  অনুযায়ী: Laura C. Coates, অন্যান্য
  প্রকাশিত: (2024-02-01)
• The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
  অনুযায়ী: Ritchlin, CT, অন্যান্য
  প্রকাশিত: (2023)
• Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
  অনুযায়ী: Siebert, S, অন্যান্য
  প্রকাশিত: (2024)
• Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis
  অনুযায়ী: Siebert, S, অন্যান্য
  প্রকাশিত: (2024)